Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/08820139.2021.1909617 http://scihub22266oqcxt.onion/10.1080/08820139.2021.1909617 33830864!ä!33830864 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Immunol+Invest 2021 ; 50 (7): 810-820 Nephropedia Template TP {{tp|p=33830864|t=2021. Better, Faster, Stronger: mRNA Vaccines Show Promise for Influenza Vaccination in Older Adults |pdf=|usr=}}{{33830864}} gab.com Text Better, Faster, Stronger: mRNA Vaccines Show Promise for Influenza Vaccination in Older Adults JO: Immunol Invest http://www.kidney.de/pget.php?&tw=1&pmid=33830864 #FOAvip Older adults have diminished immune responses that lead to increased susceptibility and severity of infectious diseases. Influenza is a leading killer of older adults despite the availability of seasonal influenza vaccination. Influenza vaccines are strain specific, and their efficacy varies greatly year to year based on how well the vaccine virus matches the circulating strains. Additionally, older adults have reduced vaccination responses. The COVID-19 pandemic highlighted the increased mortality rate in older adults for infectious disease, and brought vaccine development to the forefront. The speed of vaccine development was met with an equally impressive vaccine efficacy. Interestingly, both mRNA-based COVID-19 vaccines currently available have shown similar efficacy in both young and older adults. mRNA vaccine production has significantly reduced the production timeline compared to current influenza vaccines, making them particularly attractive for influenza vaccine development. Faster production coupled with improved efficacy would be a tremendous advancement in protecting older adults from influenza morbidity and mortality. Twit Text FOAVip Better, Faster, Stronger: mRNA Vaccines Show Promise for Influenza Vaccination in Older Adults ????Immunol Invest http://www.kidney.de/pget.php?&tw=1&pmid=33830864 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33830864 #FOAvip English Wikipedia <ref>{{Cite pmid|33830864}}</ref> Better, Faster, Stronger: mRNA Vaccines Show Promise for Influenza Vaccination in Older Adults #MMPMID33830864 Bartley JM; Cadar AN; Martin DE Immunol Invest 2021[Oct]; 50 (7): 810-820 PMID33830864show ga Older adults have diminished immune responses that lead to increased susceptibility and severity of infectious diseases. Influenza is a leading killer of older adults despite the availability of seasonal influenza vaccination. Influenza vaccines are strain specific, and their efficacy varies greatly year to year based on how well the vaccine virus matches the circulating strains. Additionally, older adults have reduced vaccination responses. The COVID-19 pandemic highlighted the increased mortality rate in older adults for infectious disease, and brought vaccine development to the forefront. The speed of vaccine development was met with an equally impressive vaccine efficacy. Interestingly, both mRNA-based COVID-19 vaccines currently available have shown similar efficacy in both young and older adults. mRNA vaccine production has significantly reduced the production timeline compared to current influenza vaccines, making them particularly attractive for influenza vaccine development. Faster production coupled with improved efficacy would be a tremendous advancement in protecting older adults from influenza morbidity and mortality. |Aged[MESH] |Animals[MESH] |Antibodies, Viral/immunology[MESH] |Humans[MESH] |Influenza A virus/*immunology[MESH] |Influenza Vaccines/*immunology[MESH] |Influenza, Human/*immunology/virology[MESH] |Orthomyxoviridae Infections/*immunology[MESH] |Pandemics/prevention & control[MESH] |Vaccination/methods[MESH] |Vaccines, Synthetic/*immunology[MESH]Better, Faster, Stronger: mRNA Vaccines Show Promise for Influenza Vac(epmc).pdf DeepDyve Pubget Overpricing